Skip to content

Kindred target upped to $13 by Barclays: ‘Solid start; potential value to come’

May 6, 2017

Barclays raised its price target on Kindred Healthcare (NYSE: KND) to $13.00 (from $11.00) while maintaining a Overweight rating, following the company’s first quarter.

Analyst Joshua Raskin notes the company provided in-line earnings per share results, but revenue figures below the Street, as the focus remains on management reshaping this entity, with additional progress towards SNF divestitures.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: